PMID- 18655913
OWN - NLM
STAT- MEDLINE
DCOM- 20080828
LR  - 20211203
IS  - 1535-6345 (Electronic)
IS  - 0147-0272 (Print)
IS  - 0147-0272 (Linking)
VI  - 32
IP  - 4
DP  - 2008 Jul-Aug
TI  - The mammalian target of rapamycin (mTOR). Foreword.
PG  - 160
LID - 10.1016/j.currproblcancer.2008.05.002 [doi]
FAU - Kummar, Shivaani
AU  - Kummar S
LA  - eng
GR  - Z99 CA999999/ImNIH/Intramural NIH HHS/United States
PT  - Introductory Journal Article
PL  - United States
TA  - Curr Probl Cancer
JT  - Current problems in cancer
JID - 7702986
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Drug Delivery Systems
MH  - Hematologic Neoplasms/*drug therapy/physiopathology
MH  - Humans
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - *Protein Kinases
MH  - TOR Serine-Threonine Kinases
PMC - PMC2529475
MID - NIHMS63379
EDAT- 2008/07/29 09:00
MHDA- 2008/08/30 09:00
PMCR- 2009/07/01
CRDT- 2008/07/29 09:00
PHST- 2008/07/29 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/29 09:00 [entrez]
PHST- 2009/07/01 00:00 [pmc-release]
AID - S0147-0272(08)00033-0 [pii]
AID - 10.1016/j.currproblcancer.2008.05.002 [doi]
PST - ppublish
SO  - Curr Probl Cancer. 2008 Jul-Aug;32(4):160. doi: 
      10.1016/j.currproblcancer.2008.05.002.